The two-dose Novavax COVID shot came to a step closer to obtaining an Emergency Use Authorization (EUA) after members of the US Food and Drug Administration (FDA) Vaccines and Related Biological Products and Advisory Committee (VRBPAC) voted 21-0 to recommend the vaccine. The report on this was written by Michael Nevradakis and published by The Defender last June 8, 2022.
Despite the vote results, the FDA committee raised the issue of heart-related adverse events found during the vaccine’s clinical trials and the vaccine’s effectiveness against new COVID variants.
Unlike the Pfizer and Moderna shots which use mRNA technology, and the Johnson & Johnson vaccine which uses adenovirus vector technology, Novavax uses the protein technology used in traditional vaccines. Because of this, the VRBPAC says that the Novavax shot might appeal to those not yet vaccinated and harboring reservations about the technologies used in current COVID shots.
Editor’s Note: It was barely a week ago when the US FDA flagged heart inflammations as a side effect of the Novavax COVID vaccinehttps://www.reuters.com/world/us/us-fda-staff-says-novavax-vaccine-lowers-covid-risk-2022-06-03/, now it is close to receiving its EUA. Is the FDA expert panel already desensitized to the devastating impact of myocarditis and pericarditis on the lives of young people?
While the expert panel thinks that heart inflammation is a “necessary risk” they are willing to take to inoculate more people, we are sure that there are people who think otherwise. Will a family who lost family members due to cardiac arrest and other heart conditions following COVID vaccination say that the vaccine was worth it?
We certainly do not think so. [See Former FDA official: FDA negligent in not investigating myocarditis cases].
Read Original Article
Click the button below if you wish to read the article on the website where it was originally published.
Click the button below if you wish to read the article offline.